Subsequently, miR-451 downregulates the expression of CXCL16 in monocytes and reduces the inflammatory milieu in the preclinical phase of RA, thereby attempting to delay the shift from the preclinical phase to the clinical manifestation of arthritis. Here, CXCL16 is linked to rheumatoid arthritis.